Du C, Chai NL, Linghu EQ, Li HK, Feng XX. Endoscopic ultrasound-guided injective ablative treatment of pancreatic cystic neoplasms. World J Gastroenterol 2020; 26(23): 3213-3224 [PMID: 32684736 DOI: 10.3748/wjg.v26.i23.3213]
Corresponding Author of This Article
En-Qiang Linghu, MD, PhD, Chief Doctor, Chief Physician, Director, Professor, Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China. linghuenqiang@vip.sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 21, 2020; 26(23): 3213-3224 Published online Jun 21, 2020. doi: 10.3748/wjg.v26.i23.3213
Endoscopic ultrasound-guided injective ablative treatment of pancreatic cystic neoplasms
Chen Du, Ning-Li Chai, En-Qiang Linghu, Hui-Kai Li, Xiu-Xue Feng
Chen Du, Ning-Li Chai, En-Qiang Linghu, Hui-Kai Li, Xiu-Xue Feng, Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Du C and Chai NL contributed equally to this article; Du C and Chai NL contributed to this paper with conception and design of the study; Du C, Chai NL, Li HK, and Feng XX did the literature review and analysis; Du C and Linghu EQ wrote the paper; all authors made the critical revision and editing of the article for important intellectual content, and approved the final version.
Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: En-Qiang Linghu, MD, PhD, Chief Doctor, Chief Physician, Director, Professor, Department of Gastroenterology and Hepatology, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing 100853, China. linghuenqiang@vip.sina.com
Received: January 13, 2020 Peer-review started: January 13, 2020 First decision: April 8, 2020 Revised: April 24, 2020 Accepted: May 22, 2020 Article in press: May 22, 2020 Published online: June 21, 2020
Core Tip
Core tip: Endoscopic ultrasound (EUS)-guided ethanol ablation was initially reported as a minimally invasive procedure to treat pancreatic cystic neoplasms (PCNs) in 2005. Several other agents, such as paclitaxel, lauromacrogol, and gemcitabine, were reported to be effective and safe for the treatment of PCNs. This treatment method has undergone much development over 15 years and is regarded as a promising treatment to replace surgical resection for PCNs. In the present review, we systematically describe the indications, contraindications, preoperative treatment, endoscopic procedure, postoperative care and follow-up, evaluation method, treatment efficiency, safety profile, tips and tricks, and current controversies and perspectives of EUS-guided injective ablation.
